start fiscal year high note revenu
out-performance margin expans
post polish result exceed consensu sale estim
nearli everi segment turn better-than-expect oper
margin expans y/i revenu growth quarter
driven particular strength diabet pain therapi brain
therapi coronari structur heart anticip headwind
exchang rate significantli higher note last quarter
vs prior increas guidanc
organ revenu growth year view quarter indic
may abl achiev promis margin improv
reach mid-singl digit revenu growth howev co still grow
slower rate larg cap med-tech name await
sign consist revenu margin remain neutral
takeaway repeat last quarter report post
sale beat busi line diabet star
revenu growth boost adopt
minim guardian connect cgm elsewher spinal cord
stimul endovascular stroke technolog drove strength
rtg control sg spend well quarter help
expand ebit margin y/i
model revis reduc sale estim slightli
larger anticip fx impact increas underli forecast
 growth near top end guidanc rang
increas spend still expect above-guid expans
ebit margin increas bp y/i
model adj ep
valuat rate neutral risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
medtron total revenu grow report basi
constant currenc basi diabet led strong top-lin beat
constant currenc growth rang spur us
launch minim system guardian connect cgm system
sugar iq well solid growth ou adopt minim
system rtg segment outperform well particularli brain
pain therapi offset in-line spine sale mig busi post
solid beat
gross margin in-lin forecast increas y/i sg
spend better model spend
revenu slightli higher forecast overal ebit margin
better forecast told combin slightli
lower tax rate ep six cent estim
actualsbtig estimate varianceww cardiac rhythm hf cardiac vascular group minim spine restor therapi diabet net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
increas constant currenc revenu growth
off-set increas estim currenc headwind report revenu
growth forecast chang adjust segment sale forecast
rest reflect guidanc
reduc model growth rate us icd us ou
pacemak heartwar busi slightli lower spine forecast
bump mitg growth meaning increas diabet revenu
forecast guid rang model y/i cc growth sale
bottom end guidanc rang full fiscal year model
top end rang y/i cc growth
nudg gross margin slightli rest year increas
 spend ebit margin estim unchang model
adjust ep guid guid
medtron rate neutral next twelv month price-to-earnings basi
share trade estim discount large-cap
med-tech peer group howev feel current valuat warrant
given slower growth vs group inconsist around revenu
oper margin perform btig provid price target
neutral-r stock risk rate includ guidanc oper
margin expans underli pressur spine market soft
emerg market margin degrad expans new busi
line competit slippag product timelin chang procedur
reimburs futur devic data fda use cash/m
bpsc growth bpsadj net bpsgross bpsebit bpssourc btig estim compani filingsnewold chang
medtron incom eproduct net y/i good gross total oper expens adj oper interest expens pre-tax incom adj net non-controlling adj net incom adjust ep share total net ex select calendar net oper ep oper net product product product oper btig estim compani report
medtron revenu ecrm heart failur structur heart y/i peripher vascular total recast y/i vascular group y/i patient monitor recoveri y/i invas group y/i recast therapi recast therapi recast therapi recast therapi group y/i group y/i y/i oper y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
